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Abstract Benzenesulfonamides bearing various substituted (hetero)aryl rings in the para−position 
were prepared by palladium nanoparticle−catalyzed Suzuki−Miyaura cross−coupling reactions and 
evaluated as human carbonic anhydrase (hCA) inhibitors against isoforms hCA I, hCA II, hCA IX 
and hCA XII. Almost all of the prepared 4−arylbenzenesulfonamides showed low inhibition against 
hCA I isoform, whereas the other cytosolic isoenzyme, hCA II was strongly affected. The major 
part of these new derivatives was potent inhibition of the tumor−associated hCA XII isoform. An 
opposite trend was observed for phenyl (4a), naphthyl (4d) and various heteroaryl (4p, 4q, 4s, 4w 
and 4x) substituted benzenesulfonamides which displayed sub−nanomolar hCA IX inhibition whilst 
poorly inhibiting the other tumor−associated isoenzyme hCA XII. The inhibition potency and 
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influence of the partially restricted aryl−aryl bond rotation on the activity/selectivity were 
rationalized by means of X−ray crystallography of the adducts of hCA II with several 
4−arylbenzenesulfonamides.  
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1. Introduction 
Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes present in most living organisms 
encoded by six genetically distinct families, the human α−, the β−, γ−, δ−, ζ− and the recently 
reported η−CAs.1 They catalyze the reversible hydration of carbon dioxide to the bicarbonate ion 
and a proton,2-3 a simple but essential reaction involved in respiration, electrolyte secretion, 
biosynthesis of several important molecules (urea, lipids, glucose, etc.), pH homeostasis and 
tumorigenicity,4,5 and are thus targets for the design of activators and inhibitors. In humans, 
activators find their pharmacological application in pathologies connected with learning and 
memory impairment,3,4,6,7 whilst inhibitors, originally used as diuretics, antiglaucoma agents or 
antiepileptics, are more recently further employed as antiobesity agents, antitumor drugs or 
diagnostic tools.3,4,6-12 In fact, the multiple pharmacological applications of CA inhibitors (CAIs) 
may be explained by the high number of isoforms and by their up− and down−regulation related to 
different pathologies. Humans express fifteen CA isoforms (hCAs), all containing a Zn(II) ion 
within the active site, but differing by their cellular localization (mitochondria, cytosol, cell 
membrane), tissues distribution and catalytic/inhibition features.4-10,13 Even if the physiological role 
of relevant CAs in diverse pathologies is more and more precisely identified, one of the main 
difficulties concerning the development of selective inhibitors is how to manage off−target 
isoenzyme inhibition. Indeed, the active site of most CA isoenzymes is a rather large conical cavity 
where the Zn(II) ion is positioned at the bottom with two adjacent halves (one hydrophobic and one 
hydrophilic) and variability between isoforms is mainly observed on the edge/entrance of the active 
site.13 
Disruption of the catalytic process occurs following several possible mechanisms: the inhibitor can 
(i) bind directly to the zinc ion,4,14-17 (ii) anchor to the zinc−coordinating water molecule/hydroxide 
ion,18-22 or (iii) bind further away from the metal ion.23,24 Zinc−binding drugs are widely 
investigated as inhibitors and the sulfonamide function, following the discovery of the exceptional 
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CA inhibitory activity of sulfanilamide,25 represents one of the most potent zinc−binding group 
(ZBG).26-28 Several primary sulfonamide derivatives, such as acetazolamide, methazolamide, 
ethoxzolamide, sulthiame, diclofenamide, dorzolamide, brinzolamide, sulpiride and zonisamide, 
have been developed and introduced in clinical use as diuretics, antiglaucoma, neuroleptic or 
antiepileptic agents (Supporting Information S1). 
Structural characterization of benzenesulfonamides in complex with hCAs showed that the 
sulfonamide function, in its deprotonated form at physiological pH, binds to the active site with 
coordination of the negatively charged nitrogen atom to the Zn(II) ion.4,27 Additionally, an extended 
network of hydrogen bonds involving residues Thr199 and Glu106 (conserved in all α−CAs) 
stabilizes the binding, whilst the phenyl ring participates in van der Waals interactions with other 
amino acid residues within the enzyme active site.4,13,29-31 Therefore, the binding mode of this 
pharmacophore appears quite similar, irrespective of the isoforms, making the rational design of 
isoenzyme−specific benzenesulfonamides CAIs a challenging program for medicinal chemists.32 
However, depending on the phenyl substituent (tail or linker moiety), more specific interactions can 
be established within the typical enzyme bipolar architecture, towards the middle part of the active 
site or towards its edge (Figure 1).4,13 
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Figure 1. Exemplified representation of the binding mode of 4−arylbenzenesulfonamides at 
physiological pH (7.4) with the active site of hCAs. The tail (aryl) interacts with hydrophobic or 
hydrophilic residues depending on its nature. 
Herein, we report the synthesis of new 4−arylbenzenesulfonamide derivatives by using the 
so−called “tail approach”, a drug design strategy based on appending scaffolds (tails) of different 
size, shape or nature to a ZBG containing pharmacophore,4,13,31,33-36 as opposed to the “ring 
approach” exploring several aromatic/heterocyclic fragments on which the ZBG is bound.4,13,36,37 
This modulation, based on the extension of benzenesulfonamide moiety by anchoring tails has been 
poorly investigated to date. The preparation of CAIs reported here was carried out by palladium 
mediated Suzuki−Miyaura cross−coupling reactions. Inhibition activity of the synthesized 
compounds was measured on tumor−associated isoenzymes hCA IX and hCA XII and on the 
physiologically dominant off−target isoforms hCA I and hCA II. To rationalize our drug design 
strategy, X−ray crystallography of several hCA II−sulfonamide adducts were also investigated. 
 
2. Results and discussion 
Inhibitor Design. The benzenesulfonamide scaffold is known for its inhibitory potency against 
CAs and 2−substituted, 2,4−disubstituted and 3,4−disubstituted derivatives were shown in many 
cases to act as weaker inhibitors compared to 4−substituted derivatives.4 Up until now, according to 
the “tail approach”, esters, amides, imines, urea and thiourea functions were commonly used linkers 
to covalently attach the tail fragment to the benzene ring.4,26,27 This approach gives higher flexibility 
to molecules but requires multi−step chemical pathways to obtain the desired compounds. The 
rationale for our drug design strategy was, on the contrary, the extension of the benzene−ZBG 
pharmacophore by anchoring an aryl moiety as a tail directly to the para position of the benzene 
ring, in the absence of any additional linker. This straightforward single−step approach, was 
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realized by using palladium catalyzed Suzuki−Miyaura cross−couplings of a unique aryl halide, 
4−iodobenzenesulfonamide 2, with a series of aryl boronic acids or esters 3a−x (Scheme 1 and 
Supporting Information, Table S1). In fact, this reaction represents a very efficient method for the 
formation of new carbon−carbon bonds,38 applicable to a wide range of aryl halides and boronic 
acids and esters39 and hereupon can be further exploited for the synthesis of molecules of biological 
interest.40,41 In this study, we prepared a library of twenty four new 4−arylbenzenesulfonamides 
(Figure 2) in which a high chemical diversity was guaranteed by a large spectrum of commercially 
available boronic acids or esters. An additional key structural element for a more efficient 
enzyme−inhibitor interaction of the biaryl moiety was represented by the finely tunable torsion 
angle derived from electrostatic interactions and/or steric repulsions. To the best of our knowledge 
such biaryl systems have not been investigated as potential CA inhibitors. Depending on the 
interactions with the active site, our new 4−arylbenzenesulfonamide derivatives can be classified 
into four families. Compounds 4a−d are ZBG−benzene−hydrophobic ring scaffolds able to interact 
with the hydrophobic region of the enzyme. Compounds 4e−k belong to a large family whose tails 
possess functionalities able to establish hydrogen bonds with the hydrophilic half. Trisaryl 
sulfonamides 4l−n constitute a further class of molecules, designed to explore deep regions within 
the enzyme. Finally, derivatives 4o−x allow investigation of both hydrophobic interactions of the 
heterocyclic moiety and the additional role of hydrogen bonding of the heteroatoms with the 
enzyme active site.  
Chemistry. 4−Iodobenzenesulfonamide 2 was obtained by an amidification reaction of the 
corresponding sulfonylchloride42 (Supporting Information, S3 and Scheme S1) while all boronic 
acids or esters 3a−x were commercially available. In a previous study,43 we explored the 
preparation (Supporting Information, S2 and Figure S2) and catalytic properties of a new 
heterogeneous catalyst comprising palladium nanoparticles stabilized by dodecanethiol and 
adsorbed on multi−walled carbon nanotubes (MWNT/PdNP@SC12H25). This composite material 
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displayed attractive catalytic function, exhibiting exemplary activity at lower catalytic loadings in 
comparison to classical homogeneous palladium complexes and excellent recyclability, showing 
good performance up to five catalytic cycles. Moreover, due to the heterogeneity of the catalytic 
system, this nanomaterial was easily removed from the reaction medium by a simple filtration. As a 
test reaction, coupling of 2 with phenylboronic acid 3a was therefore carried out using both the 
homogeneous palladium catalyst PdCl2(dppf).CH2Cl2 and the heterogeneous nanocatalyst 
MWNT/PdNP@SC12H25 (Supporting Information, Table S1). The desired cross−coupled product 
4a was obtained in only 56% yield using the PdCl2(dppf).CH2Cl2 catalyst while near quantitative 
yield (97%) was observed for the same reaction catalyzed by the more performant 
MWNT/PdNP@SC12H25 catalyst. Moreover, the high chemical yield achieved in the case of 
heterogeneous nanocatalyst is significant; sulfonamides obtained by traditional homogeneous 
catalysis often require additional purification by column chromatography, whereas the 
cross−coupling reaction using MWNT/PdNP@SC12H25 afforded compound 4a in pure form directly 
by crystallization from the reaction mixture after removal of the catalyst by filtration and 
subsequent solvent evaporation. In view of these improvements in synthetic approach, we decided 
to apply the MWNT/PdNP@SC12H25 nanocatalyst to the synthesis of all novel sulfonamides in this 
study. We prepared twenty four 4−arylbenzenesulfonamides coupling boronic acids or esters 
possessing electron withdrawing or electron donating groups and substituted at the ortho, meta or 
para positions (Supporting Information, Table S1). The products of the cross−coupling reactions 
were obtained in a range of yields from 56% to 98% (Figure 2 and Supporting Information, Table 
S1) illustrating the improved performance and versatility of this catalyst and its compatibility with 
heteroaromatic scaffolds. Indeed, only compounds 4o and 4p, obtained from the reaction with less 
reactive boronic acids 3o and 3p, were isolated in lower yields and required long reaction time as 
compared to the more reactive substrates (Supporting Information, Table S1). A long reaction time 
was also required for cross−couplings with sterically hindered ortho-substituted boronic acids 3b, 
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3c and 3t (Supporting Information, Table S1) but the corresponding products were isolated in good 
yields, confirming the efficiency of our heterogeneous catalyst in different experimental conditions. 
 
 
Scheme 1. Synthesis of 4−arylbenzenesulfonamides 4a−x using the palladium−catalyzed 
Suzuki−Miyaura cross−coupling reaction of 4−iodobenzenesulfonamide 2 and boronic acids or 
esters 3a−x. 
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Figure 2. Structures of 4−arylbenzenesulfonamides 4a−x, yields of isolated products and reaction 
time required for the cross−coupling reactions catalyzed by MWNT/PdNP@SC12H25.  
CA inhibition. Inhibition data with the new group of benzenesulfonamides 4a−x reported here, 
against the human (h) cytosolic CA isoforms hCA I and hCA II and transmembrane and 
tumor−associated isoforms hCA IX and hCA XII are shown in Table 1 and compared to the 
inhibitory activity of the standard sulfonamide inhibitor acetazolamide (AAZ). The 
structure−activity relationships (SARs) can thus be summarized as follows. 
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(i) The cytosolic and ubiquitous isoform hCA I was poorly inhibited by the majority of the 
compounds reported in this current study which exhibited KIs in a micromolar range (1−9.5 µM). 
Only derivatives 4c and 4s were between 2 and 3 times more potent than AAZ, with KIs of 146 and 
83.6 nM respectively and compounds 4a, 4p and 4q were rather effective hCA I inhibitors, 
possessing KI values in a nanomolar range (24.5−41.5 nM) and thus inhibition potency between 6 
and 10 folds higher compared to that obtained by the standard drug acetazolamide (KIAAZ = 250 
nM). On the contrary, derivatives 4l−n, 4r and 4t did not show any inhibitory activity up to 10 M 
concentration, whereas compounds 4u, 4w and 4x only moderately inhibited hCA I isoform, 
possessing inhibition constants in the range of 184.7−656 nM, similar to that of the clinically used 
agent AAZ. The low inhibition of this new series of benzenesulfonamide compounds against the 
mentioned human CA isoenzyme may represent a positive and interesting feature, since the 
ubiquitous isoform hCA I, which is abundant in red blood cells, can be certainly considered an 
important off−target when research of CAIs antitumor agents is involved.44,45 
(ii) Most of benzenesulfonamides investigated in our study behaved as very strong and effective 
inhibitors of the second cytosolic and physiologically dominant isoform hCA II, with KIs in 
sub−nanomolar/nanomolar range between 0.68 and 19.1 nM, except for compounds 4l−n and 4v 
which, possessing KIs in the range of 324−764 nM, were low potency inhibitors. Therefore, they 
were generally found to be similar or slightly better hCA II inhibitors compared to AAZ (KI = 12 
nM). Although these compounds possess a rather extensive molecular diversity, SAR is almost 
impossible to define as all substituted moieties lead to potent inhibition of this isoform.  
(iii) Derivatives 4a, 4d, 4p−q, 4s, 4w and 4x exhibited KIs for the hCA IX isoform in the range of 
0.17−0.37 nM, about two orders of magnitude lower compared to that possessed by the clinically 
used AAZ and have shown a selectivity ratio for inhibiting this transmembrane isoform over the 
cytosolic ones between 6 and 8 times higher with respect to AAZ, except for benzenesulfonamides 
4d and 4x displaying selectivity ratios as high as 4545 and 1763 over the off−target hCA I. The 
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least effective hCA IX inhibitors were derivatives 4c, 4h−n and 4r, which showed KIs in a very 
narrow range of 208−276 nM, thus being low potency inhibitors of this isoform compared to the 
clinically used inhibitor AAZ. The remaining derivatives 4e−g, 4o and 4t−v have exhibited 
moderate inhibitory potency against this isoform (KIs values between 78.1 and 159 nM).  
In the phenylsulfonylindolyl series, regioisomerism seems to play a significant role in enzyme 
inhibition. Indeed, 4t displayed weaker inhibition potency against hCA IX relative to its 
regioisomer 4s but KI values similar to those of compounds 4u and 4v, showing that probably no 
specific interactions were established by the unsubstituted NH function of derivatives 4u and 4v 
with residues in enzyme active site. When the nitrogen has been replaced by an oxygen or sulfur 
atom such as in the benzofuranyl− and benzothienylbenzenesulfonamide derivatives 4w and 4x, 
respectively, the inhibitory activity against the transmembrane hCA IX isoform highly increased 
with consequently decrease of KI values from low micromolar to sub−nanomolar range. Supposing 
that the heteroaryl moiety of 4u, 4w and 4x has the same orientation within the active site, the 
improvement of inhibition may be attributed to the capacity of oxygen or sulfur atoms to establish 
hydrogen bonds with the protein in both hCA IX and hCA II. In the case of 4s the same kind of 
hydrogen bonding may be involved with one of the two oxygens of the phenylsulfonyl group. The 
lipophilic character of the phenyl ring of the latter suggests a close contact with the hydrophobic 
half of the active site allowing the phenylsulfonyl group protected indole to occupy a binding 
position. 
(iv) Most of compounds reported in the current study showed to be very efficient hCA XII 
inhibitors possessing inhibition activity mainly at low nanomolar range and therefore of the same 
order of magnitude of AAZ. Indeed, the best inhibitors, derivatives 4c and 4e displayed even a 
sub−nanomolar KI value of 0.58 nM and compounds 4g, 4m, 4r and 4u showed inhibition potency 
against hCA XII isoform comparable to that of the clinically used AAZ with KIs in a very narrow 
range of 4.3−5.6 nM. On the contrary, derivatives 4a, 4p, 4s and 4v displayed a similar and 
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middling potency as hCA XII inhibitors, with inhibition constants in low sub−micromolar range 
between 92.7 and 760 nM, whereas 4d, 4w and 4x did not exhibit any inhibitory activity up to 
concentrations of 10 M. 
It is also important to note that this second transmembrane tumor−associated isoform, hCA XII, was 
inhibited by the new series of investigated benzenesulfonamides much more than the other 
transmembrane tumor−associated isoform, hCA IX. Indeed, the presence of a substituent in the aryl 
moiety (tail) at the ortho position, likely affecting the rotation ability of the benzenesulfonamide 
derivatives, appears to reduce the inhibitory activity against the hCA IX isoform and improve the 
inhibition potency against the hCA XII (compare, as an example, compounds 4a, 4b and 4c). The 
selectivity ratio for inhibiting the target hCA XII isoform over the cytosolic and off−target hCA II 
for most of this series of derivatives is rather low compared to that shown by the standard AAZ, 
except for derivatives 4l−n. In particular, derivative 4m represents the best selective inhibitor of the 
series against the tumor−associated isoform hCA XII over the cytosolic hCA II.  
We can conclude that most of the sulfonamides belonging to this new series of derivatives obtained 
using an innovative synthetic pathway, have shown to possess high inhibition potency against the 
tumor−associated target isoforms, having on the other hand good selectivity ratios over the 
off−target cytosolic isoforms, in particular against hCA I. 
 
Table 1. Inhibition data of human CA isoforms hCA I, II, IX and XII with 
4−arylbenzenesulfonamide drugs 4a−x and the standard sulfonamide inhibitor acetazolamide 
(AAZ) by a stopped flow CO2 hydrase assay.
46 Colors coding in the tails refers as follow: pink is 
indicative of hydrophobic rings (derivatives 4a−4d); green refers to aryl possessing functionalities 
able to establish hydrogen bonds (derivatives 4e−4k); magenta codes tails in trisaryl sulfonamides 
(derivatives 4l−4n); blue relates to heteroaromatic scaffolds (derivatives 4o−4x). 
Drug Ar KI
a (nM)  Selectivityb,c 
13 
 
hCA I hCA II hCA IX hCA XII  I/IX II/IX I/XII II/XII 
4a 
 
41.5 0.79 0.21 92.7  198 3.8 0.5 0.009 
4b 
 
3499 1.2 20.1 47.0  174 0.06 74.5 0.03 
4c 
 
146 0.98 208 0.58  0.7 0.005 252 1.7 
4d 
 
1000 0.69 0.22 /d  4545 3.1 /e /e 
4e 
 
1178 2.1 98.5 0.58  12.0 0.02 2031 3.6 
4f 
 
6965 14.2 159 19.5  43.8 0.09 357 0.7 
4g 
 
2340 9.3 126 4.3  18.6 0.07 544 2.2 
4h 
 
3701 12.3 235 36.5  15.7 0.05 101 0.3 
4i 
 
1335 1.2 228 14.2  5.9 0.005 94.0 0.08 
4j 
 
6966 11.1 216 38.3  32.3 0.05 182 0.3 
4k 
 
9516 19.1 259 32.2  36.7 0.07 296 0.6 
4l 
 
/d 764 224 54.2  /e 3.4 /e 14.1 
4m 
 
/d 324 240 4.9  /e 1.4 /e 66.1 
4n 
 
/d 397 276 55.6  /e 1.4 /e 7.1 
4o 
 
2397 16.6 78.1 20.3  30.7 0.2 118 0.8 
4p 
 
35.2 2.5 0.18 760  196 13.9 0.05 0.003 
4q 
 
24.5 0.95 0.17 65.0  149 5.6 0.4 0.01 
4r 
 
/d 18.0 258 5.2  40.1 0.07 1992 3.5 
14 
 
4s 
 
83.6 0.68 0.24 96.7  348 2.8 0.9 0.007 
4t 
 
/d 11.7 100 33.9  229 0.1 674 0.3 
4u 
 
656 10.2 124 5.6  4.6 0.08 101 1.8 
4v 
 
2645 764 156 415  17.0 4.9 6.4 1.8 
4w 
 
184.7 0.70 0.37 /d  499 1.9 /e /e 
4x 
 
370.3 0.84 0.21 /d  1763 4.0 /e /e 
AAZ 
 
250.0 12.1 25 5.7  10.0 0.5 43.9 2.1 
 
a Errors within the range of  5−10 % of the reported values, from 3 different assays (data not 
shown).b Selectivity ratios between KIs of hCA I or hCA II and hCA IX.  
c Selectivity ratio between 
hCA I or hCA II and hCA XII. d Not active  >10000 nM. e  Not determined. 
 
Crystallography. X−ray crystallography of hCA II adducts with sulfonamides 4c, 4g and 4h were 
investigated in this study (Figure 3 and Supporting Information, Table S2). At physiological pH 
conditions, the three inhibitors were found within the hCA II active site in the deprotonated 
sulfonamide form: the negatively charged nitrogen atom coordinates to the Zn(II) ion and is 
involved in a strong hydrogen bond with the OH group of Thr199 residue. Additionally, one of the 
sulfonamide oxygens establishes a hydrogen bond with the NH amide of Thr199. These strong ionic 
and hydrogen bond interactions are thus involved in the stabilization of the enzyme−inhibitor 
adducts. The three inhibitors were found in a similar conformation where the dihedral angles of the 
directly attached phenyl rings are close to 120° for 4c and 45° for both 4g and 4h. Aminophenyl 
derivatives 4g and 4h superpose almost perfectly and the nitrogen atom of their aniline moiety 
establishes hydrogen bonds with two and one water molecules, respectively. Hydrophobic 
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interactions are observed between the aryl rings of 4g and 4h and residues Thr200, Leu198 and 
Phe131. This great similarity concerning the orientations and interactions of 4g and 4h vs. the hCA 
II active site may explain the close KI values of 9.3 and 12.3 nM, respectively (Table 1). 
Benzenesulfonamide 4c bearing an ortho− isopropyl group on the tail phenyl ring orients differently 
as compared to derivatives 4g and 4h. In fact, as illustrated in Figure 3, the ortho−isopropylphenyl 
ring system better accommodates the hydrophobic pocket as compared to the other two derivatives, 
establishing van der Waals interactions with both residues Phe131 and Val121. This more efficient 
fitting may be the origin of a higher inhibition potency of 4c (KI = 0.98 nM) against hCA II. 
   
Figure 3. Superposition of sulfonamides 4c (brown), 4g (blue) and 4h (green) bound to hCA II 
active site in the corresponding enzyme−inhibitor adducts. The sulfonamide function is depicted as 
sticks, the labeled Zn(II) ion is the gray sphere, two of its three ligands (His96 and 119) and 
residues in the binding of the inhibitors are also shown. Water molecules coordinated to the 
nitrogen atom of the aniline moiety are represented as red spheres. 
 
3. Conclusion 
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We reported the preparation of a series of new 4−arylbenzenesulfonamide derivatives and their 
biological evaluations as carbonic anhydrase inhibitors. The so−called “tail approach” drug−design 
strategy was based on an efficient palladium nanoparticles (MWNT/PdNP@SC12H25) catalyzed 
Suzuki−Miyaura cross−coupling reactions allowing a wide pharmacomodulation of the aryl moiety. 
Enzyme inhibition assays displayed low inhibitory potency for almost the whole collection of 
compounds against cytosolic hCA I isoenzyme, while the other cytosolic one, hCA II, was strongly 
affected by most of the derivatives (except for 4l−4n and 4v). Benzenesulfonamides bearing phenyl 
(4a), naphthyl (4d) and some bicyclic heteroaryl (4p, 4q, 4s, 4w, 4x) rings showed sub−nanomolar 
(KI = 0.17−0.37 nM) inhibition against the tumor−associated hCA IX isoenzyme with very high 
selectivity (from 382 to more than 105) vs. the other tumor−associated hCA XII isoenzyme. Most of 
the prepared derivatives were potent hCA XII inhibitors (KI = 4.3-38.3 nM), comparable to the 
clinically used acetazolamide (AAZ). Bulky tails such as ortho and meta substituted phenyl rings 
probably affect the aryl−aryl bond rotation which may explain the high potency observed for 
derivatives 4c and 4e. X−Ray crystallography of hCA II−4c adduct evidenced a different active−site 
occupancy of 4c within hCA II and consequently an improved inhibition activity owing to a 
restricted aryl−aryl bond rotation. The selectivity of the prepared compounds against the 
tumor−associated hCA XII vs. the cytosolic isoenzyme hCA II remained rather low with respect to 
the standard reference AAZ except for functionalized trisaryl derivatives. These findings shed light 
on the importance of the finely tunable 4−aryl substituted benzenesulfonamides as potent and 
selective hCA inhibitors and on the basis of these preliminary results, the design of next generation 
inhibitors will be engaged. 
4. Experimental section 
General 
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All solvents were of reagent grade and, when necessary, purified and dried by standard methods. 
All reagents were purchased from Sigma−Aldrich, Alfa Aesar and TCI and used without further 
purification. Carbon nanostructures − MWNT (Baytubes C150P, made by chemical vapor 
deposition) were obtained from Bayer Material Science and treated with concentrated hydrochloric 
acid prior to use to minimize the content of residual metal catalyst from synthesis (Supporting 
Information, S2.1). All glassware was cleaned with a mixture of hydrochloric and nitric acid (3:1 
v/v, ‘aqua regia’) and rinsed thoroughly with deionized water, cleaned with potassium hydroxide in 
isopropyl alcohol and finally rinsed with deionized water. Reactions and products were monitored 
by thin layer chromatography (TLC) on silica gel (KIESELGEL 60 F254, Merck). Column 
chromatography purifications were performed on CHROMAGEL® Silice 60 ACC 70−200 µm silica 
gel. Melting points were determined on a Stuart SMP3 Melting Point Apparatus (capillary tube). IR 
spectra were measured on a Perkin−Elmer Spectrum BX FTIR instrument. NMR spectra were 
recorded on a Bruker AC−300 spectrometer (1H at 300 MHz and 13C at 75 MHz) at 298K using 
DMSO−d6 as solvent. All 1H NMR and 13C NMR spectra are reported in δ units (ppm) using TMS 
as internal standard. Coupling constants J are expressed as s, brs, d, dd, ddd, td, t, dt, q and m and 
correspond to singlet, broad singlet, doublet, doublet of doublets, doublet of doublet of doublets, 
triplet of doublets, triplet, doublet of triplets, quarter and multiplet, respectively. Mass spectra were 
recorded on a GCT Waters apparatus using ammonia chemical ionization (CI, HRMS) or electron 
impact ionization (EI, HRMS). Thermogravimetric analysis was performed using a TA Instruments 
SDT Q600 under a flow of air at a rate of 90 mL min−1 at a heating rate of 10 oC min−1 from room 
temperature to 1000 oC. Transmission electron microscopy (TEM) was performed using a JEOL 
2100F TEM (field emission gun source, information limit < 0.19 nm) at room temperature. Analysis 
of nanoparticle size was conducted using Gatan DigitalMicrograph software. Energy dispersive 
X−ray analysis was performed using an Oxford Instruments INCA 560 X−ray microanalysis 
system. TEM samples were prepared by drop−drying methanolic solutions onto a copper grid 
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mounted “lacey” carbon films. Elemental analyses were carried out using a Perkin Elmer CHN 
2400 apparatus. Purity of the final products (4a-x) was checked by elemental analysis (± 0.4 % of 
the theoretical values) and by NMR spectra (Supporting Information, S5).  
 
General procedure for the synthesis of 4−arylbenzenesulfonamides 4a−x 
4−Arylbenzenesulfonamides 4a−x were prepared using the Suzuki−Miyaura cross−coupling 
reaction of 4−iodobenzenesulfonamides 2 with boronic acids or esters 3a−x in a method analogous 
to that outlined in our previous study (Supporting Information, S4).41 In a typical procedure, 2 
(56.8−170.4 mg, 0.2−0.6 mmol, 1.0−2.0 eq.), 3a−x (48.7−271.4 mg, 0.27−1.04 mmol, 1.3−2.6 eq.), 
sodium acetate (38.5−114.8 mg, 0.47−1.4 mmol, 2.3−4.6 eq.) and MWNT/PdNP@SC12H25 (2.5−7.6 
mg, 2−4 mol %) were placed in a two−necked round−bottomed flask under an inert atmosphere of 
argon. A degassed solution of methanol (15 mL) was added via cannula and the resulting 
suspension stirred at 70 °C.  After cooling to room temperature, the suspension was filtered through 
a PTFE membrane filter (pore diameter 0.2 μm) and the obtained filtrate concentrated to dryness. 
The crude solids were then recrystallized from methanol or purified by flash column 
chromatography on a silica gel (Supporting Information, S4). 
4−(Phenyl)benzenesulfonamide (4a). White solid, 100%. mp: 226 °C. νmax (KBr) / cm−1: 3344 (s) 
(SO2NH2), 3251 (CH), 1295 (s) (SO2NH2), 1168 (s) (SO2NH2), 1155 (s), 1101. 
1H NMR (300 MHz, 
DMSO−d6) δ (ppm): 7.95− (m, 4H, H−2, H−6, H−3 and H−5), 7.75 (dd, J = 7.1, 1.6 Hz, 2H, 
H−2′ and H−6′ or H−3′ and H−5′), 7.57− (m, 2H, H−2′ and H−6′ or H−3′ and H−5′), 7.49− 
(m, 1H, H−4′), 7.43 (s, 2H, SO2NH2). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 143.6 (C), 143.2 
(C), 138.9 (C), 129.3 (2 × CH), 128.6 (CH−4′), 127.4 (2 × CH), 127.2 (2 × CH), 126.5 (2 × CH). 
MS (EI) m/z (%): 233 (100, [M]+), 153 (65, [M]+ − SO2NH2), 152 (64). HRMS (EI) calcd for 
C12H11NO2S [M]
+ 233.0511. Found 233.0513. Anal. Calcd for C12H11NO2S: C, 61.78; H, 4.75; N, 
6.00; S, 13.75. Found: C, 61.48; H, 4.64; N, 5.98; S, 13.39. 
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4−(2−Methylphenyl)benzenesulfonamide (4b). White solid, 86%. mp: 157 °C. νmax (KBr) / cm−1: 
3359 (SO2NH2), 3266 (CH), 1323 (s) (SO2NH2), 1305 (s), 1148 (s) (SO2NH2), 1099. 
1H NMR (300 
MHz, DMSO−d6) δ (ppm): 7.90 (d, J = 7.9 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.56 (d, J = 7.9 
Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.44 (s, 2H, SO2NH2), 7.38−7.20 (m, 4H, H−3′, H−4′, 
H−5′ and H−6′), 2.25 (s, 3H, CH3). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 144.9 (C), 142.8 (C), 
140.1 (C), 134.9 (C), 130.7 (CH), 129.7 (CH−2 and CH−6 or CH−3 and CH−5), 129.6 (CH), 128.2 
(CH), 126.3 (CH), 125.8 (CH−2 and CH−6 or CH−3 and CH−5), 20.3 (CH3). MS (EI) m/z (%): 247 
(99, [M]+), 167 (78, [M]+ − SO2NH2), 166 (64), 165 (100), 152 (59). HRMS (EI) calcd for 
C13H13NO2S [M]
+ 247.0667. Found 247.0671. Anal. Calcd for C13H13NO2S: C, 63.13; H, 5.30; N, 
5.66; S, 12.97. Found: C, 62.84; H, 5.15; N, 5.87; S, 12.71. 
4−(2−iso−propylphenyl)benzenesulfonamide (4c). White solid, 82%. mp: 162 °C. νmax (KBr) / 
cm−1: 3339 (SO2NH2), 3240 (CH), 2946 (CH), 1316 (s) (SO2NH2), 1142 (s) (SO2NH2), 1096. 
1H 
NMR (300 MHz, DMSO−d6) δ (ppm): 7.90 (d, J = 8.0 Hz, 2H, H−2 and H−6 or H−3 and H−5), 
7.50 (d, J = 8.0 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.51−7.38 (m, 2H), 7.44 (s, 2H, SO2NH2), 
7.28 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 7.5 Hz, 1H), 2.91 (q, J = 6.8 Hz, 1H, CH(CH3)2), 1.14 (d, J = 
6.8 Hz, 6H, CH(CH3)2). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 145.8 (C), 145.1 (C), 142.9 (C), 
139.4 (C), 129.8 (CH−2 and CH−6 or CH−3 and CH−5), 129.6 (CH), 128.6 (CH), 126.0 (CH), 
125.9 (CH), 125.8 (CH−2 and CH−6 or CH−3 and CH−5), 29.3 (CH(CH3)2), 24.2 (CH(CH3)2). MS 
(EI) m/z (%): 275 (35, [M]+), 195 (10, [M]+ − SO2NH2), 180 (100), 165 (70). HRMS (EI) calcd for 
C15H17NO2S [M]
+ 275.0980. Found 275.0985. Anal. Calcd for C15H17NO2S: C, 65.43; H, 6.22; N, 
5.09; S, 11.64. Found: C, 65.21; H, 6.22; N, 5.25; S, 11.60. 
4−(2−naphthalenyl)benzenesulfonamide (4d). White solid, 83%. mp: 266 °C. νmax (KBr) / cm−1:  
3302 (SO2NH2), 3235 (CH), 1323 (s) (SO2NH2), 1166 (s) (SO2NH2), 1093. 
1H NMR (300 MHz, 
DMSO−d6) δ (ppm): 8.35 (s, 1H, H−1′), 8.11−7.95 (m, 7H), 7.93 (dd, J = 8.7, 1.5 Hz, 1 H), 
7.64−7.55 (m, 2H), 7.46 (s, 2H, SO2NH2). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 143.2 (C), 
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143.0 (C), 136.0 (C), 133.2 (C), 132.6 (C), 128.7 (CH), 128.4 (CH), 127.6 (CH), 127.4 (2 × CH), 
126.7 (2 × CH), 126.4 (2 × CH), 126.0 (CH), 125.0 (CH). MS (EI) m/z (%): 283 (100, [M]+), 204 
(56), 203 (59, [M]+ − SO2NH2), 202 (72). HRMS (EI) calcd for C16H13NO2S [M]+ 283.0667. Found 
283.0665. Anal. Calcd for C16H13NO2S: C, 67.82; H, 4.62; N, 4.94; S, 11.32. Found: C, 67.46; H, 
4.68; N, 4.86; S, 11.18. 
4−(3−formylphenyl)benzenesulfonamide (4e). White solid, 98%. mp: 116 °C. νmax (KBr) / cm−1: 
3308 (SO2NH2), 3230 (CH), 1685 (s) (C=O), 1339 (s) (SO2NH2), 1181, 1163 (s) (SO2NH2), 1096. 
1H NMR (300 MHz, DMSO−d6) δ (ppm): 10.13 (s, 1H, CHO), 8.30 (s, 1H, H−2′), 8.12 (d, J = 7.8 
Hz, 1H), 8.01−7.93 (m, 5H), 7.77 (t, J = 7.8 Hz, 1H), 7.46 (s, 2H, SO2NH2). 13C NMR (75 MHz, 
DMSO−d6) δ (ppm): 193.3 (CHO), 143.7 (C−SO2NH2), 142.2 (C), 139.7 (C), 137.1 (C), 133.2 
(CH), 130.3 (CH), 129.1 (CH), 128.5 (CH), 127.6 (CH−2 and CH−6 or CH−3 and CH−5), 126.6 
(CH−2 and CH−6 or CH−3 and CH−5). MS (EI) m/z (%): 261 (100, [M]+), 181 (32, [M]+ − 
SO2NH2), 152 (99). HRMS (EI) calcd for C13H11NO3S [M]
+ 261.0460. Found 261.0465. Anal. 
Calcd for C13H11NO3S: C, 59.76; H, 4.24; N, 5.36; S, 12.27. Found: C, 59.84; H, 4.05; N, 5.26; S, 
12.40. 
4−(3−methoxycarbonylphenyl)benzenesulfonamide (4f). White solid, 83%. mp: 177 °C. νmax 
(KBr) / cm−1: 3333 (SO2NH2), 3245 (CH), 1716 (s) (C=O), 1326 (s) (SO2NH2), 1248, 1179 (s) 
(SO2NH2), 1083. 
1H NMR (300 MHz, DMSO−d6) δ (ppm): 8.27 (t, J = 1.7 Hz, 1H, H−2′), 
8.08−8.01 (m, 2H), 7.95 (brs, 4H, H−2, H−3, − and H−6), 7.70 (t, J = 7.8 Hz, , H−5′), 7.47 (s, 
2H, SO2NH2), 3.91 (s, 3H, OCH3). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 166.2 (C=O), 143.7 
(C), 142.4 (C), 139.5 (C), 132.1 (CH), 130.7 (C), 130.0 (CH), 129.2 (CH), 127.6 (CH−2 and CH−6 
or CH−3 and CH−5), 126.7 (CH−2 and CH−6 or CH−3 and CH−5), 52.3 (OCH3). MS (EI) m/z (%): 
291 (100, [M]+), 260 (71, [M]+ − OCH3), 152 (73). HRMS (EI) calcd for C14H13NO4S [M]+ 
291.0565. Found 291.0570. Anal. Calcd for C14H13NO4S: C, 57.72; H, 4.50; N, 4.81; S, 11.01. 
Found: C, 57.46; H, 4.51; N, 4.85; S, 10.91. 
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4−(3−aminophenyl)benzenesulfonamide (4g). Brown solid, 94%. mp: 231 °C. νmax (KBr) / cm−1: 
3385 (s) (NH2), 3341 (SO2NH2), 3302 (CH), 1323 (s) (SO2NH2), 1158 (s) (SO2NH2), 1096. 
1H 
NMR (300 MHz, DMSO−d6) δ (ppm): 7.89 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and H−5), 
7.75 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.40 (s, 2H, SO2NH2), 7.15 (t, J = 7.8 Hz, 
1H), 6.90 (s, 1H, H−2′), 6.85 (d, J = 7.8 Hz, 1H), 6.64 (dd, J = 7.8, 1.2 Hz, 1H), 5.25 (s, 2H, NH2). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 149.5 (C−NH2), 144.6 (C), 142.8 (C), 139.7 (C), 129.8 
(CH), 127.1 (CH−2 and CH−6 or CH−3 and CH−5), 126.4 (CH−2 and CH−6 or CH−3 and CH−5), 
114.7 (CH), 114.1 (CH), 112.4 (CH). MS (EI) m/z (%): 248 (100, [M]+), 168 (45, [M]+ − SO2NH2). 
HRMS (EI) calcd for C12H12N2O2S [M]
+ 248.0619. Found 248.0624. Anal. Calcd for C12H12N2O2S: 
C, 58.05; H, 4.87; N, 11.28; S, 12.91. Found: C, 57.70; H, 4.89; N, 11.38; S, 12.74. 
4−(4−aminophenyl)benzenesulfonamide (4h). Yellow solid, 98%. mp: 266 °C. νmax (KBr) / cm−1: 
3426 (s) (NH2), 3339 (SO2NH2), 3286 (CH), 1326 (s) (SO2NH2), 1155 (s) (SO2NH2), 1096. 
1H 
NMR (300 MHz, DMSO−d6) δ (ppm): 7.81 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and H−5), 
7.73 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.46 (d, J = 8.4 Hz, 2H, H−2′ and H−6′ or 
H−3′ and H−5′), 7.32 (s, 2H, SO2NH2), 6.67 (d, J = 8.4 Hz, 2H, H−2′ and H−6′ or H−3′ and H−5′), 
5.42 (s, 2H, NH2). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 149.6 (C−NH2), 144.1 (C−SO2NH2), 
141.1 (C), 127.8 (2 × CH), 126.4 (2 × CH), 125.6 (C), 125.5 (2 × CH), 114.4 (CH−2′ and CH−6′ or 
CH−3′ and CH−5′). MS (EI) m/z (%): 248 (100, [M]+), 168 (38, [M]+ − SO2NH2). HRMS (EI) calcd 
for C12H12N2O2S [M]
+ 248.0619. Found 248.0623. Anal. Calcd for C12H12N2O2S: C, 58.05; H, 4.87; 
N, 11.28; S, 12.91. Found: C, 57.70; H, 4.91; N, 11.48; S, 12.69. 
4−(4−cyanophenyl)benzenesulfonamide (4i). White solid, 100%. mp: 181 °C. νmax (KBr) / cm−1: 
3344 (SO2NH2), 3245 (CH), 2222 (s) (CN), 1326 (s) (SO2NH2), 1148 (s) (SO2NH2), 1091. 
1H NMR 
(300 MHz, DMSO−d6) δ (ppm): 8.04−7.92 (m, 8H), 7.48 (s, 2H, SO2NH2). 13C NMR (75 MHz, 
DMSO−d6) δ (ppm): 144.3 (C), 143.4 (C), 141.6 (C), 133.2 (CH−2′ and CH−6′ or CH−3′ and 
CH−5′), 128.2 (2 × CH), 127.9 (2 × CH), 126.6 (2 × CH), 118.9 (C−CN), 111.1 (C−CN). MS (EI) 
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m/z (%): 258 (100, [M]+), 178 (80, [M]+ − SO2NH2), 151 (51). HRMS (EI) calcd for C13H10N2O2S 
[M]+ 258.0463. Found 258.0469. Anal. Calcd for C13H10N2O2S: C, 60.45; H, 3.90; N, 10.85; S, 
12.41. Found: C, 60.09; H, 3.75; N, 10.78; S, 12.02. 
4−{4−[(1H−pyrazol−1−yl)methyl]phenyl}benzenesulfonamide (4j). Yellow solid, 83%. mp: 233 
°C. νmax (KBr) / cm−1: 3354 (SO2NH2), 3318 (CH), 1326 (s) (SO2NH2), 1153 (s) (SO2NH2), 1099. 
1H NMR (300 MHz, DMSO−d6) δ (ppm): 7.93−7.83 (m, 5H), 7.72 (d, J = 8.2 Hz, 2H, H−2′ and 
H−6′ or H−3′ and H−5′), 7.50 (d, J = 1.9 Hz, 1H, H−3′′ or H−5′′), 7.42 (s, 2H, SO2NH2),  7.35 (d, J 
= 8.2 Hz, 2H, H−2′ and H−6′ or H−3′ and H−5′), 6.31 (t, J = 1.9 Hz, 1H, H−4′′), 5.40 (s, 2H, CH2). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 143.2 (C−SO2NH2 and C), 139.3 (CH−3′′ or CH−5′′), 
138.2 (C), 138.1 (C), 130.5 (CH−3′′ or CH−5′′), 128.4 (2 × CH), 127.4 (2 × CH), 127.3 (2 × CH), 
126.5 (2 × CH), 105.8 (CH−4′′), 54.4 (CH2). MS (EI) m/z (%): 313 (82, [M]+), 312 (100), 246 (68, 
[M]+ − C3H3N2), 233 (9, [M]+ − SO2NH2), 165 (65). HRMS (EI) calcd for C16H15N3O2S [M]+ 
313.0885. Found 313.0887. Anal. Calcd for C16H15N3O2S: C, 61.32; H, 4.82; N, 13.41; S, 10.23. 
Found: C, 60.99; H, 4.70; N, 13.21; S, 9.91. 
4−(3,4,5−trimethoxyphenyl)benzenesulfonamide (4k). White solid, 85%. mp: 160 °C. νmax (KBr) 
/ cm−1: 3313 (SO2NH2), 3230 (CH), 1326 (s) (SO2NH2), 1248 (s) (OCH3), 1163 (s) (SO2NH2), 1122 
(s). 1H NMR (300 MHz, DMSO−d6) δ (ppm): 7.94− (m, 4H, H−2, H−6, H−3 and H−5), 7.42 (s, 
2H, SO2NH2), 7.01 (s, 2H, H−2′ and H−6′), 3.89 (s, 6H, OCH3−3′ and OCH3−5′), 3.71 (s, 3H, 
OCH3−4′). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 153.3 (C−3′−OCH3 and C−5′−OCH3), 143.5 
(C), 142.8 (C), 137.8 (C), 134.4 (C), 127.2 (CH−2 and CH−6 or CH−3 and CH−5), 126.1 (CH−2 
and CH−6 or CH−3 and CH−5), 104.4 (CH−2′ and CH−6′), 60.1 (C−4′−OCH3), 56.0 (C−3′−OCH3 
and C−5′−OCH3). MS (EI) m/z (%): 323 (100, [M]+), 308 (78, [M]+ − CH3). HRMS (EI) calcd for 
C15H17NO5S [M]
+ 323.0827. Found 323.0843. Anal. Calcd for C15H17NO5S: C, 55.71; H, 5.30; N, 
4.33; S, 9.92. Found: C, 55.37; H, 5.29; N, 4.50; S, 9.77. 
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4−[4−(4−bromophenyl)phenyl]benzenesulfonamide (4l). Pale pink solid, 80%. mp: 330 °C. νmax 
(KBr) / cm−1: 3333 (SO2NH2), 3245 (CH), 1313 (s) (SO2NH2), 1158 (s) (SO2NH2), 1101, 801 (s) 
(C−Br). 1H NMR (300 MHz, DMSO−d6) δ (ppm): 7.99−7.80 (m, 8H), 7.76−7.67 (m, 4H), 7.45 (s, 
2H, SO2NH2). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 143.3 (C), 142.8 (C), 138.9 (C), 138.8 (C), 
138.2 (C), 132.1 (2 × CH), 129.0 (2 × CH), 127.9 (2 × CH), 127.5 (2 × CH), 127.3 (2 × CH), 126.6 
(2 × CH), 121.4 (C−Br). MS (EI) m/z (%): 389 (100, [81BrM]+), 387 (97, [79BrM]+), 344 (52), 342 
(51), 309 (21, [81BrM]+ − SO2NH2), 307 (20, [79BrM]+ − SO2NH2), 228 (81), 226 (65). HRMS (EI) 
calcd for C18H14NO2S
81Br [M]+ 386.9929. Found 386.9940. Anal. Calcd for C18H14NO2SBr: C, 
55.68; H, 3.63; N, 3.61; S, 8.26. Found: C, 55.31; H, 3.73; N, 3.30; S, 7.89. 
[1,1′:4′,1′′−terphenyl]−4,4′′−disulfonamide (4m). White solid, 91%. mp: 333 °C. νmax (KBr) / 
cm−1: 3344 (SO2NH2), 3266 (CH), 1326 (s) (SO2NH2), 1150 (s) (SO2NH2), 1099. 
1H NMR (300 
MHz, DMSO−d6) δ (ppm): 8.01−7.88 (m, 12H), 7.46 (s, 4H, SO2NH2−4 and SO2NH2−4′′). 13C 
NMR (75 MHz, DMSO−d6) δ (ppm): 143.4 (2 × C), 142.8 (2 × C), 138.7 (2 × C), 128.0 (4 × CH), 
127.4 (4 × CH), 126.6 (4 × CH). MS (EI) m/z (%): 388 (100, [M]+), 308 (27, [M]+ − SO2NH2), 228 
(41, [M]+ − 2 × SO2NH2). HRMS (EI) calcd for C18H16N2O4S2 [M]+ 388.0552. Found 388.0570. 
Anal. Calcd for C18H16N2O4S2: C, 55.65; H, 4.15; N, 7.21; S, 16.51. Found: C, 55.63; H, 4.10; N, 
6.89; S, 16.15. 
[1,1′:3′,1′′−terphenyl]−4,4′′−disulfonamide (4n). White solid, 94%. mp: 310 °C. νmax (KBr) / 
cm−1: 3370 (SO2NH2), 3251 (CH), 1331, 1318 (s) (SO2NH2), 1145 (s) (SO2NH2), 1091. 
1H NMR 
(300 MHz, DMSO−d6) δ (ppm): 8.07 (t, J = 1.6 Hz, 1H, H−2′), 8.03 (d, J = 8.5 Hz, 4H, H−2, H−6, 
H−2′′ and H−6′′ or H−3, H−5, H−3′′ and H−5′′), 7.94 (d, J = 8.5 Hz, 4H, H−2, H−6, H−2′′ and H−6′′ 
or H−3, H−5, H−3′′ and H−5′′), 7.82 (dd, J = 7.4, 1.6 Hz, 2H, H−4′ and H−6′), 7.67 (dd, J = 7.4, 1.6 
Hz, 1H, H−5′), 7.45 (s, 4H, SO2NH2−4 and SO2NH2−4′′). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 
143.4 (2 × C), 143.3 (2 × C), 139.8 (2 × C), 130.1 (CH−2′ or CH−5′), 127.7 (CH−2, CH−6, CH−2′′ 
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and CH−6′′ or CH−3, CH−5, CH−3′′ and CH−5′′), 127.2 (CH−4′ and CH−6′), 126.5 (CH−2, CH−6, 
CH−2′′ and CH−6′′ or CH−3, CH−5, CH−3′′ and CH−5′′), 126.0 (CH−2′ or CH−5′). MS (EI) m/z 
(%): 388 (100, [M]+), 308 (35, [M]+ − SO2NH2), 228 (39, [M]+ − 2 × SO2NH2). HRMS (EI) calcd 
for C18H16N2O4S2 [M]
+ 388.0552. Found 388.0557. Anal. Calcd for C18H16N2O4S2: C, 55.65; H, 
4.15; N, 7.21; S, 16.51. Found: C, 55.26; H, 4.22; N, 7.12; S, 16.16. 
4−(3−pyridinyl)benzenesulfonamide (4o). Yellow solid, 67%. mp: 200 °C. νmax (KBr) / cm−1: 
3297 (SO2NH2), 3127 (CH), 1334 (s) (SO2NH2), 1166 (s) (SO2NH2), 1093. 
1H NMR (300 MHz, 
DMSO−d6) δ (ppm): 8.98 (d, J = 2.1 Hz, 1H, H−2′), 8.65 (dd, J = 4.8, 1.5 Hz, 1H, H−4′), 8.18 (ddd, 
J = 8.0, 2.1, 1.5 Hz, 1H, H−6′), 8.00−7.90 (m, 4H, H−2, H−6, H−3 and H−5), 7.56 (dd, J = 8.0, 4.8 
Hz, 1H, H−5′), 7.47 (s, 2H, SO2NH2). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 149.5 (CH−2′ or 
CH−4′), 148.1 (CH−2′ or CH−4′), 143.8 (C−SO2NH2), 140.5 (C−4), 134.7 (CH−5′ or CH−6′), 134.2 
(C−1′), 127.7 (CH−2 and CH−6 or CH−3 and CH−5), 126.6 (CH−2 and CH−6 or CH−3 and CH−5), 
124.2 (CH−5′ or CH−6′). MS (EI) m/z (%): 234 (100, [M]+), 154 (79, [M]+ − SO2NH2). HRMS (EI) 
calcd for C11H10N2O2S [M]
+ 234.0463. Found 234.0470. Anal. Calcd for C11H10N2O2S: C, 56.39; 
H, 4.30; N, 11.96; S, 13.69. Found: C, 56.08; H, 4.23; N, 11.98; S, 13.38. 
4−(3−quinolinyl)benzenesulfonamide (4p). White solid, 56%. mp: 247 °C. νmax (KBr) / cm−1: 
3318 (SO2NH2), 3137 (CH), 1328 (s) (SO2NH2), 1163 (s) (SO2NH2), 1096. 
1H NMR (300 MHz, 
DMSO−d6) δ (ppm): 9.33 (d, J = 2.1 Hz, 1H, H−2′), 8.78 (d, J = 2.1 Hz, 1H, H−4′), 8.13 (d, J = 8.3 
Hz, 2H, H−2 and H−6 or H−3 and H−5), 8.11 (d, J = 7.3 Hz, 2H, H−5′ and H−8′), 8.00 (d, J = 8.3 
Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.84 (td, J = 7.3, 1.0 Hz, 1H, H−6′ or H−7′), 7.70 (td, J = 
7.3, 1.0 Hz, 1H, H−6′ or H−7′), 7.49 (s, 2H, SO2NH2). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 
149.5 (CH−2′), 147.3 (C−8′a), 143.8 (C−SO2NH2), 140.5 (C), 133.9 (CH), 131.6 (C), 130.3 (CH), 
128.9 (CH), 128.8 (CH), 127.9 (CH−2 and CH−6 or CH−3 and CH−5), 127.7 (C), 127.4 (CH), 
126.7 (CH−2 and CH−6 or CH−3 and CH−5). MS (EI) m/z (%): 284 (100, [M]+), 204 (62, [M]+ − 
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SO2NH2). HRMS (EI) calcd for C15H12N2O2S [M]
+ 284.0619. Found 284.0626. Anal. Calcd for 
C15H12N2O2S: C, 63.36; H, 4.25; N, 9.85; S, 11.28. Found: C, 62.95; H, 4.31; N, 9.70; S, 10.90. 
4−(1H−indol−5−yl)benzenesulfonamide (4q). Beige solid, 83%. mp: 248 °C. νmax (KBr) / cm−1: 
3421 (s) (NH−1’), 3328 (SO2NH2), 3230 (CH), 1323 (s) (SO2NH2), 1313 (s), 1142 (s) (SO2NH2), 
1093. 1H NMR (300 MHz, DMSO−d6) δ (ppm): 11.26 (NH−1’), 7.99−7.83 (m, 5H), 7.57−7.40 (m, 
3H), 7.39 (s, 2H, SO2NH2), 6.54 (s, 1H, H−4′). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 145.4 
(C−7′a), 141.9 (C−SO2NH2), 136.2 (C), 130.0 (C), 128.5 (C), 127.1 (CH−2 and CH−6 or CH−3 and 
CH−5), 126.7 (CH), 126.5 (CH−2 and CH−6 or CH−3 and CH−5), 120.6 (CH), 119.0 (CH), 112.2 
(CH−7′), 102.0 (CH−2′ or CH−3′). MS (EI) m/z (%): 272 (100, [M]+), 192 (36, [M]+ − SO2NH2). 
HRMS (EI) calcd for C14H12N2O2S [M]
+ 272.0619. Found 272.0621. Anal. Calcd for C14H12N2O2S: 
C, 61.75; H, 4.44; N, 10.29; S, 11.77. Found: C, 61.38; H, 4.32; N, 10.21; S, 11.47. 
4−(5−benzo[d][1,3]dioxolyl)benzenesulfonamide (4r). White solid, 100%. mp: 226 °C. νmax (KBr) 
/ cm−1: 3333 (SO2NH2), 3259 (CH), 1320 (s) (SO2NH2), 1230 (OCH2), 1155 (s) (SO2NH2), 1096. 
1H 
NMR (300 MHz, DMSO−d6) δ (ppm): 7.89− (m, 4H, H−2, H−6, H−3 and H−5), 7.40 (s, 2H, 
SO2NH2), 7.36 (d, J = 1.7 Hz, 1H, H−4′), 7.26 (dd, J = 8.1, 1.7 Hz, 1H, H−6′), 7.06 (d, J = 8.1, Hz, 
1H, H−7′), 6.10 (s, 2H, CH2). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 148.4 (C−O−1′ or C−O−3′), 
147.8 (C−O−1′ or C−O−3′), 143.2 (C), 142.6 (C), 133.0 (C), 127.0 (CH−2 and CH−6 or CH−3 and 
CH−5), 126.4 (CH−2 and CH−6 or CH−3 and CH−5), 121.1 (CH), 109.0 (CH), 107.6 (CH), 101.6 
(CH2). MS (EI) m/z (%): 277 (100, [M]
+), 197 (36, [M]+ − SO2NH2), 139 (51). HRMS (EI) calcd for 
C13H11N2O4S [M]
+ 277.0409. Found 277.0407. Anal. Calcd for C13H11N2O4S: C, 56.31; H, 4.00; N, 
5.05; S, 11.56. Found: C, 55.94; H, 3.97; N, 5.11; S, 11.36. 
4−(1−phenylsulfonyl−1H−indol−3−yl)benzenesulfonamide (4s). White solid, 90%. mp: 219 °C. 
νmax (KBr) / cm−1: 3359 (SO2NH2), 3256 (CH), 1326 (s) (SO2NH2), 1168 (s) (SO2Ph), 1160 (s) 
(SO2NH2), 1132 (s) (SO2Ph), 1088. 
1H NMR (300 MHz, DMSO−d6) δ (ppm): 8.31 (s, 1H, H−2’), 
8.18−8.03 (m, 3H), 8.02−7.87 (m, 5H), 7.78−7.58 (m, 3H), 7.53−7.34 (m, 2H), 7.46 (s, 2H, 
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SO2NH2). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 143.1 (C−SO2NH2), 137.0 (C), 136.0 (C), 
135.1 (CH, C), 134.9 (C), 130.2 (2 × CH), 128.2 (2 × CH), 127.2 (2 × CH), 126.5 (2 × CH), 125.6 
(CH), 125.1 (CH), 124.4 (CH), 121.8 (C), 120.6 (CH), 113.7 (CH−7’). MS (EI) m/z (%): 412 (65, 
[M]+), 271 (100, [M]+ − SO2Ph). HRMS (EI) calcd for C20H16N2O4S2 [M]+ 412.0552. Found 
412.0537. Anal. Calcd for C20H16N2O4S2: C, 58.24; H, 3.91; N, 6.79; S, 15.55. Found: C, 57.93; H, 
3.91; N, 6.63; S, 15.20. 
4−(1−phenylsulfonyl−1H−indol−2−yl)benzenesulfonamide (4t). White solid, 79%. mp: 178 °C. 
νmax (KBr) / cm−1: 3364 (SO2NH2), 3251 (CH), 1383 (s) (SO2Ph), 1305 (s) (SO2NH2), 1184 (s) 
(SO2Ph), 1161 (s) (SO2NH2), 1088. 
1H NMR (300 MHz, DMSO−d6) δ (ppm): 8.15 (d, J = 8.3 Hz, 
1H), 7.94 (d, J = 8.2 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.80 (d, J = 8.2 Hz, 2H, H−2 and H−6 
or H−3 and H−5), 7.66−7.39 (m, 7H), 7.44 (s, 2H, SO2NH2), 7.37−7.28 (m, 1H), 7.00 (s, 1H, H−3′). 
13C NMR (75 MHz, DMSO−d6) δ (ppm): 144.0 (C−SO2NH2), 140.5 (C), 137.9 (C), 135.8 (C), 
135.5 (C), 134.7 (CH), 130.5 (C), 130.4 (2 × CH), 129.6 (2 × CH), 126.5 (2 × CH), 125.8 (CH), 
125.3 (2 × CH), 125.2 (CH), 121.7 (CH), 116.3 (CH−3′ or CH−7′), 116.0 (CH−3′ or CH−7′). MS 
(EI) m/z (%): 412 (78, [M]+), 271 (100, [M]+ − SO2Ph), 191 (86), 110 (82). HRMS (EI) calcd for 
C20H16N2O4S2 [M]
+ 412.0552. Found 412.0553. Anal. Calcd for C20H16N2O4S2: C, 58.24; H, 3.91; 
N, 6.79; S, 15.55. Found: C, 57.91; H, 3.90; N, 6.65; S, 15.32. 
4−(1H−indol−2−yl)benzenesulfonamide (4u). White solid, 60%. mp: 302 °C. νmax (KBr) / cm−1: 
3431 (s) (NH−1’), 3339 (SO2NH2), 3251 (CH), 1297 (s) (SO2NH2), 1161 (s) (SO2NH2), 1096. 1H 
NMR (300 MHz, DMSO−d6) δ (ppm): 11.71 (s, 1H, NH−1′), 8.05 (d, J = 8.5 Hz, 2H, H−2 and H−6 
or H−3 and H−5), 7.89 (d, J = 8.5 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.59 (d, J = 7.9 Hz, 1H, 
H−4′ or H−7′), 7.44 (d, J = 7.9 Hz, 1H, H−4′ or H−7′), 7.40 (s, 2H, SO2NH2), 7.16 (td, J = 7.9, 1.7 
Hz, 1H, H−5′ or H−6′), 7.08 (d, J = 1.7 Hz, 1H, H−3′), 7.04 (t, J = 7.9 Hz, 1H, H−5′ or H−6′). 13C 
NMR (75 MHz, DMSO−d6) δ (ppm): 142.6 (C−SO2NH2), 137.7 (C), 136.2 (C), 135.5 (C), 128.6 
(C), 126.5 (2 × CH), 125.3 (2 × CH), 122.6 (CH), 120.7 (CH), 119.9 (CH), 111.7 (CH−7′), 100.9 
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(CH). MS (EI) m/z (%): 272 (100, [M]+), 192 (41, [M]+ − SO2NH2). HRMS (EI) calcd for 
C14H12N2O2S [M]
+ 272.0619. Found 272.0626. Anal. Calcd for C14H12N2O2S: C, 61.75; H, 4.44; N, 
10.29; S, 11.77. Found: C, 61.51; H, 4.43; N, 10.16; S, 11.41. 
4−(5−methoxy−1H−indol−2−yl)benzenesulfonamide (4v). White solid, 61%. mp: 265 °C. νmax 
(KBr) / cm−1: 3364 (s) (NH−1′), 3339 (SO2NH2), 3235 (CH), 1326 (s) (SO2NH2), 1220 (s) (OCH3), 
1155 (s) (SO2NH2), 1093. 
1H NMR (300 MHz, DMSO−d6) δ (ppm): 11.55 (s, 1H, NH−1′), 8.02 (d, 
J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.88 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and 
H−5), 7.39 (s, 2H, SO2NH2), 7.33 (d, J = 8.8 Hz, 1H, H−7′), 7.07 (d, J = 2.3 Hz, 1H, H−4′), 6.99 (s, 
1H, H−3′), 6.81 (dd, J = 8.8, 2.3 Hz, 1H, H−6′), 3.78 (s, 3H, OCH3). 13C NMR (75 MHz, 
DMSO−d6) δ (ppm): 154.0 (C−OCH3), 142.4 (C−SO2NH2), 136.6 (C), 135.6 (C), 132.9 (C), 129.0 
(C), 126.5 (CH−2 and CH−6 or CH−3 and CH−5), 125.1 (CH−2 and CH−6 or CH−3 and CH−5), 
113.1 (CH), 112.5 (CH), 101.8 (CH), 100.7 (CH), 55.4 (OCH3). MS (EI) m/z (%): 302 (100, [M]
+), 
287 (44, [M]+ − CH3). HRMS (EI) calcd for C15H14N2O3S [M]+ 302.0725. Found 302.0733. Anal. 
Calcd for C15H14N2O3S: C, 59.59; H, 4.67; N, 9.27; S, 10.61. Found: C, 59.19; H, 4.63; N, 9.38; S, 
10.34. 
4−(2−benzo[b]furanyl)benzenesulfonamide (4w). White solid, 83%. mp: 272 °C. νmax (KBr) / 
cm−1: 3339 (SO2NH2), 3261 (CH), 1291 (s) (SO2NH2), 1155 (s) (SO2NH2), 1099. 
1H NMR (300 
MHz, DMSO−d6) δ (ppm): 8.13 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.95 (d, J = 8.4 
Hz, 2H, H−2 and H−6 or H−3 and H−5), 7.73 (d, J = 7.5 Hz, 1H, H−4′ or H−7′), 7.69 (d, J = 7.5 Hz, 
1H, H−4′ or H−7′), 7.65 (s, 1H, H−3′), 7.47 (s, 2H, SO2NH2), 7.40 (td, J = 7.5, 1.2 Hz, 1H, H−5′ or 
H−6′), 7.32 (t, J = 7.5 Hz, 1H, H−5′ or H−6′). 13C NMR (75 MHz, DMSO−d6) δ (ppm): 154.7 (C−2′ 
or C−7′a), 153.9 (C−2′ or C−7a′), 144.0 (C−SO2NH2), 132.8 (C), 128.8 (C), 126.7 (CH−2 and 
CH−6 or CH−3 and CH−5), 125.6 (CH), 125.2 (CH−2 and CH−6 or CH−3 and CH−5), 123.7 (CH), 
121.8 (CH), 111.5 (CH), 104.5 (CH). MS (EI) m/z (%): 273 (100, [M]+), 193 (25, [M]+ − SO2NH2), 
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165 (44). HRMS (EI) calcd for C14H11NO3S [M]
+ 273.0460. Found 273.0458. Anal. Calcd for 
C14H11NO3S: C, 61.52; H, 4.06; N, 5.12; S, 11.73. Found: C, 61.28; H, 4.03; N, 5.15; S, 11.72. 
4−(2−benzo[b]thienyl)benzenesulfonamide (4x). White solid, 87%. mp: 314 °C. νmax (KBr) / 
cm−1: 3344 (SO2NH2), 3245 (CH), 1308 (s) (SO2NH2), 1163 (s) (SO2NH2), 1096. 
1H NMR (300 
MHz, DMSO−d6) δ (ppm): 8.09−7.97 (m, 4H), 7.93 (d, J = 8.4 Hz, 2H, H−2 and H−6 or H−3 and 
H−5), 7.91 (s, 1H, H−3′), 7.48 (s, 2H, SO2NH2), 7.46−7.39 (m, 2H). 13C NMR (75 MHz, 
DMSO−d6) δ (ppm): 143.8 (C), 141.7 (C), 140.5 (C), 139.2 (C), 136.8 (C), 126.8 (CH−2 and CH−6 
or CH−3 and CH−5), 126.6 (CH−2 and CH−6 or CH−3 and CH−5), 125.5 (CH), 125.3 (CH), 124.4 
(CH), 122.8 (CH), 122.2 (CH). MS (EI) m/z (%): 289 (100, [M]+), 209 (32, [M]+ − SO2NH2). 
HRMS (EI) calcd for C14H11NO2S2 [M]
+ 289.0231. Found 289.0231. Anal. Calcd for C14H11NO2S2: 
C, 58.11; H, 3.83; N, 4.84; S, 22.16. Found: C, 57.83; H, 3.60; N, 4.72; S, 22.56. 
 
CA Inhibition Assay 
An Applied Photophysics stopped−flow instrument has been used for assaying the CA catalyzed 
CO2 hydration activity.
46 Phenol red (at a concentration of 0.2 mM) has been used as indicator, 
working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.4), 10 mM Tris·HCl and 
0.1 M NaSO4 (for maintaining constant the ionic strength), following the initial rates of the 
CA−catalyzed CO2 hydration reaction for a period of 10−100 s. The CO2 concentrations ranged 
from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For 
each inhibitor, at least six traces of the initial 5−10% of the reaction have been used for determining 
the initial velocity. The non−catalyzed rates were determined in the same manner and subtracted 
from the total observed rates. Stock solutions of inhibitor (10 mM) were prepared in 
distilled−deionized water and dilutions up to 0.01 nM were done thereafter with distilled−deionized 
water. Inhibitor and enzyme solutions were pre−incubated together for 15 minutes at room 
temperature prior to assay, in order to allow for the formation of the E−I complex. The inhibition 
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constants were obtained by non−linear least−squares methods using PRISM 3, whereas the kinetic 
parameters for the uninhibited enzymes from Lineweaver−Burk plots, as reported earlier46 and 
represent the mean from at least three different determinations. All CAs were recombinant proteins 
obtained as reported earlier by these groups.4445,47 
Co−crystallization and X−ray data collection 
Crystals of hCA II complexed with compounds 4c, 4g and 4h were obtained using the sitting drop 
vapor diffusion method. An equal volume of 0.8 mM solution of hCA II in Tris pH 8.0 and 1.6 mM 
of the inhibitors in Hepes 20 mM pH 7.4 was mixed and incubated for 15 minutes. 2 µL of the 
complex solution were mixed with 2 µL of a solution of 1.6 M sodium citrate, 50 mM Tris pH 8.0 
and were equilibrated against the same solution at 296 K. Crystals of the complex grew in a few 
days. The crystals were flash−frozen at 100 K using a solution obtained by adding 25% (v/v) 
glycerol to the mother liquor solution as cryoprotectant. Data on crystals of the complexes were 
collected using synchrotron radiation at the BM30A beamline at ESRF (Grenoble, France) with a 
wavelength of 0.980 Å and an ADSC Q315r CCD detector. Data were integrated and scaled using 
the program XDS.48 Data processing statistics are showed in the Supporting Information, Table S2. 
Structure determination 
The crystal structure of hCA II (PDB accession code: 4FIK) without solvent molecules and other 
heteroatoms was used to obtain initial phases of the structures using Refmac5.49 5% of the unique 
reflections were selected randomly and excluded from the refinement data set for the purpose of 
Rfree calculations. The initial |Fo − Fc| difference electron density maps unambiguously showed the 
inhibitor molecules. An electron density, which could be interpreted as a second molecule of 
inhibitor 4g, was present near the N−terminal region of the protein. Thus, a second 4g molecule was 
introduced in the model and refined with unitary occupancy. Moreover, after the introduction of 
molecule 4c, residual electron densities were present in the Fo − Fc map and they were interpreted 
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as water molecules at partial occupancy. Also, a partial occupancy was assigned to the atoms of 
compound 4c. Atomic models for inhibitors were calculated and the energy minimized using the 
program JLigand 1.0.39. Refinements proceeded using normal protocols of positional, isotropic 
atomic displacement parameters alternating with manual building of the models using COOT.50 
Solvent molecules were introduced automatically using the program ARP.51 The quality of the final 
models were assessed with COOT and Rampage.52 Crystal parameters and refinement data are 
summarized in the Supporting Information, Table S2. Atomic coordinates were deposited in the 
Protein Data Bank (PDB accession code: 5E28, 5E2K, 5E2S). Graphical representations were 
generated with Chimera.53 
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